Ascentage Pharma Group (AAPGV) - Total Utang marang Modal

Simbol lan logo merek Ascentage Pharma Group (AAPGV)

Ascentage Pharma Group (AAPGV) attracts leading biochemists with large-scale developments in the field of apoptosis, supporting its scientific staff through RSU packages. The price action on the total debt-to-equity chart is 3.90. Management with global experience is successfully advancing clinical trials in the US and China, while a stable cash flow ensures the commercial success of the drug Olverembatinib in treating leukemias.

AAPGV: Total Utang marang Modal Ascentage Pharma 25.01.2025 - 29.10.2026

Rincian analitis perusahaan Ascentage Pharma Group

- kuotasi lan prakiraan analis:
Kutipan saham Ascentage Pharma|AAPGV - Bagan rega target
- indikator kapitalisasi pasar:
Kapitalisasi pasar Ascentage Pharma|AAPGV - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- indikator kapitalisasi buku:
Nilai Buku saben Saham Ascentage Pharma|AAPGV - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku ascentage.com|AAPGV - Total Aset Bisnis
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Ascentage Pharma Group|AAPGV - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Ascentage Pharma Group|AAPGV - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Ascentage Pharma|AAPGV - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Ascentage Pharma|Rasio cepet ascentage.com
- informasi bathi lan kelipatan valuasi:
AAPGV - Penghasilan resik
Analisis fundamental perusahaan:AAPGV, Ascentage Pharma
Produk dadi Ascentage

The peak of innovation activity at Ascentage Pharma Group (AAPGV) regarding the development of oncology inhibitors requires significant capital expenditures for clinical trials. By analyzing the financial risk metric (debt-to-equity), an investor assesses the proportion of borrowed funds relative to equity, which determines the business's level of dependence on creditors and the balance sheet structure's resilience to potential cash flow gaps during scaling.

Analisis pesaing Ascentage Pharma Group

Rasio Total Utang marang Ekuitas ONC|Utang marang Ekuitas HALO|Total Utang marang Modal RVMD|Rasio Total Utang marang Ekuitas Ascentage Pharma Corp AAPG|Total Utang marang Modal CGON (CG Oncology, Inc.)|Total Utang marang Modal urogen.com URGN|BCAX - Utang marang Ekuitas|PSNL (Personalis Inc) - Rasio Utang marang Ekuitas|ERAS: Total Utang marang Modal|Rasio Total Utang marang Ekuitas Delcath Corp|YMAB (Y-mAbs Therapeutics) - Total Utang marang Modal|Utang marang Modal aurabiosciences.com AURA|Utang marang Ekuitas Candel Therapeutics (CADL)|ARAY (Accuray Inc) - Rasio Kabeh Utang marang Dana Pribadi|SELLAS Life Sciences Group - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ACTU|Citius Oncology, Inc. - Total Utang marang Modal|TuHURA Biosciences, Inc. (HURA) - Rasio Total Utang marang Ekuitas|TARA (Protara Therapeutics, Inc.) - Rasio Total Utang marang Ekuitas|Fate Therapeutics Inc (FATE) - Total Utang marang Modal|Utang marang Ekuitas Aadi Bioscience, Inc.|TCRX: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal CSBR|XBIT - Utang marang Modal|Total Utang marang Modal CVM (CEL-SCI)|Total Utang marang Modal OS Therapies Inc. OSTX|RADX - Utang marang Ekuitas|Koefisien Total Utang marang Modal Artiva Biotherapeutics, Inc. ARTV|ANL: Total Utang marang Modal|Rasio Total Utang marang Ekuitas verupharma.com|TPST (Tempest Therapeutics, Inc.) - Total Utang marang Modal|Utang marang Modal Xilio XLO|Utang marang Ekuitas Renovaro Inc. (RENB)|muraloncology.com - Rasio Utang marang Ekuitas|Kairos Pharma - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal OKUR (OnKure Therapeutics, Inc.)|CytoMed - Total Utang marang Modal|CRIS - Total Utang marang Modal|APLM: Total Utang marang Modal|Rasio Utang marang Modal Tharimmune Corporation THAR|ADVB (Advanced Biomed Inc.) - Total Utang marang Modal|Utang marang Modal genprex.com GNPX|Rasio Total Utang marang Ekuitas CLDI (Calidi Biotherapeutics)|SBFM (Sunshine Biopharma Inc.) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Xenetic Biosciences, Inc. XBIO|SLRX (Salarius Pharma) - Utang Agregat marang Ekuitas|Purple Biotech - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi AONC (American Oncology Network)|BGNE: Total Utang marang Modal|Checkpoint Therapeutics Inc. (CKPT) - Total Utang marang Modal|Utang marang Ekuitas Elevation Oncology, Inc.|ICAD: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Ikena Oncology, Inc. (IKNA)|Rasio Total Utang marang Ekuitas notablelabs.com NTBL|Total Utang marang Modal VIRX (Viracta Therapeutics, Inc.)|Total Utang marang Modal MorphoSys Inc MOR|NAYA: Rasio Total Utang marang Ekuitas